Been digging into the psychedelic medicine space and there's actually some interesting stuff happening here worth paying attention to. Back in 2022 when Oregon became the first state to officially legalize magic mushrooms, it sparked this whole wave of investment into psilocybin mushroom stocks and related therapies. The sector was getting serious momentum at that time.

The psychedelic medicine market was projected to hit around $8 billion by 2029, growing at roughly 13% annually. Companies were raising serious capital too - funding had jumped to over $700 million by 2021, which was insane compared to just $90 million in 2019. Psilocybin treatments showed real promise for anxiety, depression, addiction, and other mental health issues. This wasn't fringe stuff anymore.

Looking back at the three companies that were getting attention back then: MindMed was developing psilocybin-based therapies for addiction and anxiety, running clinical trials on micro-dosed LSD treatments. Stock was trading around $1.07 at the time but had taken a beating, down about 22% that year. Cybin out of Toronto was also in the game, working on rapid-delivery systems for psychedelic treatments. They were down even more, around 27.5% YTD, partly due to pipeline delays. Then there was Field Trip Health, another Toronto outfit focused on depression treatments using psilocybin combined with psychotherapy. Their stock had dropped 46% since the start of the year to around $1.32.

All three were getting hammered in the broader market downturn, but the interesting part was that the psychedelic medicine thesis itself wasn't really the problem. These psilocybin mushroom stocks represented an emerging sector that was still finding its footing. Field Trip was actually expanding operations globally despite the stock price action, and the others were progressing through clinical trials.

It's one of those spaces where the long-term thesis could be solid even if the near-term volatility is brutal. The regulatory environment was clearly shifting in favor of these treatments, which is usually the biggest hurdle for biotech companies developing novel therapies. Whether you're looking at this from a medical innovation angle or just tracking emerging market trends, the psychedelic sector was definitely worth monitoring back then.